Quantcast

Latest Hyperthermia therapy Stories

2008-09-30 09:01:00

SALT LAKE CITY, Sept. 30, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) today announced the purchase of two new BSD-500 hyperthermia cancer therapy systems in Poland from the Holy Cross Hospital (Swietokrzkzyskie Cancer Center) in Kielce, Poland and the Center of Oncology Maria Sklodowska-Curie Memorial Institute in Krakow, Poland. These two cancer centers join six other centers that have purchased hyperthermia systems from BSD Medical in Poland, and the many BSD hyperthermia...

2008-09-23 09:01:09

SALT LAKE CITY, Sept. 23, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that the addition of hyperthermia to chemotherapy was recommended as standard therapy for soft tissue sarcoma by the European Society for Medical Oncology (ESMO), the leading European professional medical oncology organization comprising a network of more than 5,000 oncology professionals in over 100 countries. The use of hyperthermia as standard treatment for soft tissue sarcomas was debated...

2008-09-18 09:00:49

SALT LAKE CITY, Sept. 18, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that it will attend and have an exhibit at the 50th ASTRO (American Society for Therapeutic Radiology and Oncology) annual conference to be held at the Boston Convention and Exhibition Center in Boston, Massachusetts on September 21 - September 25, 2008. ASTRO's annual conference is the largest radiation oncology conference held in America and the premier worldwide scientific meeting in...

2008-09-15 09:00:57

SALT LAKE CITY, Sept. 15, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today reported that a new article in Current Option in Oncology (see 2008, 20:pages 438-443) highlights strong success from the use of the BSD-2000 manufactured by BSD Medical Corporation, in treating patients with high risk soft tissue sarcomas. Central to the article's review of sarcoma studies using the BSD-2000 is the results of a phase III study involving 341 randomized patients with high risk soft...

2008-07-10 09:01:29

SALT LAKE CITY, July 10, 2008 (PRIME NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) today announced that the company has filed its third quarter 10-Q report with the Securities and Exchange Commission and has released the following highlights of year-to-date results after three quarters of its fiscal year 2008: * Sales were up 66% compared to the prior year * Gross margin rose from 41% in the prior year to 63% for the current year * Operating expenses decreased, compared...

2008-07-03 09:01:19

BSD Medical Corp. (NASDAQ:BSDM) today announced the addition of seven new BSD-500 hyperthermia systems purchased by major cancer treatment center in the United States. The most recent purchase by the Massey Cancer Center at Virginia Commonwealth University located in Richmond, Virginia joins in a number of recent hyperthermia system sales in the United States. Other notable cancer care hospitals that have also purchased or installed BSD hyperthermia systems this year include: 1 Cleveland...

2008-06-25 09:03:33

BSD Medical Corp. (NASDAQ:BSDM) today announced that another BSD-2000 hyperthermia system has been purchased, installed and is now in use in China, at the Liaocheng Peoples Hospital located in Liaocheng City, in the Western Shandong Province of the People's Republic of China. The Liaocheng Peoples Hospital has recently added a 19-floor, state-of-the-art building equipped with the most up-to-date cancer imaging and therapy devices in the world. This hospital serves as the main cancer center to...

2008-06-18 09:01:17

BSD Medical Corp. (NASDAQ: BSDM) today reported that in the Annals of Oncology (Volume 19, Supplement 2, 2008), the European Society for Medical Oncology (ESMO) Clinical Treatment Guideline Working Group has published its relevant clinical treatment guidelines under "Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up." The guidelines highlight hyperthermia therapy as a treatment option for several types of soft tissue sarcomas. The ESMO Guidelines...

2007-11-20 09:01:08

BSD Medical Corp. (AMEX:BSM) today announced the installation of the first BSD-500 hyperthermia cancer therapy system in Switzerland at the Department of Radiation Oncology of Kantonsspital Aarau. The hospital joins BSD's growing family of prestigious global customers with the purchase and installation of the new hyperthermia therapy system. The BSD-500 will be used to increase the Department's cancer therapy technology, particularly in treating advanced and recurrent cancer patients....

2007-09-13 09:00:39

BSD Medical Corp. (AMEX: BSM) today announced that it has received an order for a new BSD-2000/3D/MR system to be installed at the University of Dusseldorf. This purchase was made possible by a multi-million Euro donation from the Parents' Initiative Pediatric Cancer Clinic. For more than 10 years the Dusseldorf pediatric oncology department has pioneered the application of hyperthermia therapy for treating children's cancers using a standard BSD-2000 for the treatment of soft tissue...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related